Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
FAM193A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
5 August 2026
A visual target evaluation report for FAM193A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
FAM187B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
5 August 2026
A visual target evaluation report for FAM187B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
FAM187A Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
5 August 2026
A visual target evaluation report for FAM187A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
FAM186B Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
5 August 2026
A visual target evaluation report for FAM186B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
WWP2 Biologics Sequence Review Report 2026: NEDD4-like E3 ubiquitin-protein ligase WWP2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of WWP2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EIF3F Biologics Sequence Review Report 2026: Eukaryotic translation initiation factor 3 subunit F Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of EIF3F protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CBX4 Biologics Sequence Review Report 2026: E3 SUMO-protein ligase CBX4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CBX4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
RNF103 Biologics Sequence Review Report 2026: E3 ubiquitin-protein ligase RNF103 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of RNF103 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HAS3 Biologics Sequence Review Report 2026: Hyaluronan synthase 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of HAS3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NDUFS8 Biologics Sequence Review Report 2026: NADH dehydrogenase iron-sulfur protein 8, mitochondrial Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of NDUFS8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EYA2 Biologics Sequence Review Report 2026: Protein phosphatase EYA2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of EYA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ACOT7 Biologics Sequence Review Report 2026: Cytosolic acyl coenzyme A thioester hydrolase Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ACOT7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.